Premium
[O4–01–05]: CARDIOMETABOLIC RISK PREDICTS BIOMARKER PROGRESSION IN ALZHEIMER's DISEASE TRAJECTORY
Author(s) -
Daniela Femminella Grazia,
TaylorDavies Genevieve,
Scott James,
Edison Paul
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.07.421
Subject(s) - biomarker , medicine , cohort , framingham risk score , disease , oncology , apolipoprotein e , risk assessment , psychology , biology , computer science , biochemistry , computer security
performance or accelerated declined is small to medium in all subdomains. Conclusions:The results suggest that although the differences are subtle or not evident in the early stage post T2D diagnosis, and probably do not cause functional disability yet, the effect of T2D on cognition starts relatively early in the course of the disease. This suggests that an annual evaluation of all cognitive subdomains, starting already at the prediabetes stage, may be advantageous. Deciphering the patterns of cognitive decline is of importance for better prevention, diagnosis, and treatment of the possible deleterious effect of T2D on cognition, and eventually frank dementia.